HBIO Harvard Bioscience Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: HBIO

Price (delayed)

$6.655

Market cap

$30.3M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.31

Enterprise value

$66.4M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 40

Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production ...

Highlights
Harvard Bioscience's revenue has increased by 2.7% from the previous quarter
The gross profit has grown by 2.2% since the previous quarter
HBIO's quick ratio has soared by 143% YoY but it is down by 7% QoQ
The company's net income has surged by 82% YoY but it fell by 6% QoQ
The equity has dropped by 53% year-on-year and by 26% since the previous quarter
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: http://www.harvardbioscience.com
Peers: BRKR A TMO JNJ

Key stats

What are the main financial stats of HBIO

HBIO stock price

How has the Harvard Bioscience stock price performed over time
Intraday
-0.22%
1 week
2.86%
1 month
12.23%
1 year
36.09%
YTD
-0.52%
QTD
8.21%

Financial performance

How have Harvard Bioscience's revenue and profit performed over time
Revenue
$87.81M
Gross profit
$51.07M
Operating income
-$245,000
Net income
-$10.41M
Gross margin
58.2%
Net margin
-11.9%
Harvard Bioscience's operating margin has plunged by 200% from the previous quarter but it has soared by 99% YoY
HBIO's operating income has dropped by 185% since the previous quarter but it has surged by 100% year-on-year
The company's net income has surged by 82% YoY but it fell by 6% QoQ
Harvard Bioscience's net margin has soared by 82% YoY but it has decreased by 4.4% from the previous quarter

Price vs fundamentals

How does HBIO's price correlate with its fundamentals

Growth

What is Harvard Bioscience's growth rate over time

Valuation

What is Harvard Bioscience stock price valuation
P/E
N/A
P/B
4.05
P/S
0.34
EV/EBIT
N/A
EV/EBITDA
38.99
EV/Sales
0.76
The EPS has soared by 82% YoY but it has contracted by 5% from the previous quarter
HBIO's price to book (P/B) is 76% more than its 5-year quarterly average of 2.3 and 69% more than its last 4 quarters average of 2.4
The equity has dropped by 53% year-on-year and by 26% since the previous quarter
The stock's price to sales (P/S) is 72% less than its 5-year quarterly average of 1.2 but 13% more than its last 4 quarters average of 0.3
Harvard Bioscience's revenue has increased by 2.7% from the previous quarter

Efficiency

How efficient is Harvard Bioscience business performance
HBIO's return on invested capital has surged by 94% year-on-year and by 15% since the previous quarter
The ROS has soared by 93% YoY and by 7% from the previous quarter
The return on assets has surged by 76% year-on-year but it has declined by 7% since the previous quarter
The return on equity has grown by 36% year-on-year but it has declined by 26% since the previous quarter

Dividends

What is HBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HBIO.

Financial health

How did Harvard Bioscience financials performed over time
The total assets is 11% more than the total liabilities
HBIO's quick ratio has soared by 143% YoY but it is down by 7% QoQ
HBIO's current ratio has surged by 131% year-on-year but it is down by 6% since the previous quarter
The company's debt to equity has surged by 116% YoY and by 35% QoQ
The equity has dropped by 53% year-on-year and by 26% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.